Rosenberg Clinical Cancer Center at Beth Israel Deaconess Medical Center in Boston, Massachusetts, in the United States; he also heads its hematology/oncology division.
He specializes in pancreatic cancer.
His research has included development of anti-cancer drugs such as erlotinib, nab-paclitaxel and temsirolimus, and the development of patient-derived tumor xenograft models.